Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.51 |
| ▸ | CRHR1 | P34998 | 8/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787092 | 0.81 | CRHR1 (0.43) | NPY1RCRHR1 | |
| SCHEMBL5789861 | 0.80 | CRHR1 (0.43) | NPY1RCRHR1 | |
| SCHEMBL5599408 | 0.79 | CRHR1 (0.40) | CRHR1TSHR | |
| SCHEMBL5789232 | 0.75 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL5611176 | 0.75 | CRHR1 (0.65) | NPY1RCRHR1 | |
| SCHEMBL5790000 | 0.75 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL5785875 | 0.75 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL27650874 | 0.74 | NPY1R (0.50) | NPY1RCRHR1 | |
| SCHEMBL5787088 | 0.74 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL5789272 | 0.73 | CRHR1 (0.60) | NPY1RCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007522200-A | — | — | 2007-08-09 | — | — | JP | claimed |
| EP-1718311-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-11-08 | — | — | EP | claimed |
| EP-0923582-B1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | PFIZER (US) | 2006-09-20 | — | — | EP | claimed |
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | PFIZER INC | 2005-09-22 | — | — | US | claimed |
| WO-2005079807-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-6900217-B2 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC (US) | 2005-05-31 | — | — | US | claimed |
| US-20050009823-A1 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC | 2005-01-13 | — | — | US | claimed |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | PFIZER INC | 2004-04-29 | — | — | US | claimed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | claimed |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | PFIZER INC. | 2002-10-24 | — | — | US | claimed |
| US-20020151713-A1 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC. | 2002-10-17 | — | — | US | claimed |
| US-6432989-B1 | TREATING SLEEP DISORDERS | PFIZER INC | 2002-08-13 | — | — | US | claimed |
| US-20010041673-A1 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | PFIZER INC. | 2001-11-15 | — | — | US | claimed |
| EP-1149583-A2 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| US-20010007867-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | CHEN YUHPYNG L (US) | 2001-07-12 | — | — | US | claimed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | claimed |
| EP-1082960-A2 | Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | claimed |
| EP-0923582-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1999-06-23 | — | — | EP | claimed |
| WO-1998008847-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1998-03-05 | — | — | WO | claimed |
| EP-1718311-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1703918-A2 | COMBINATION OF CRF ANTAGONISTS AND 5-HT 1B RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-0923582-B1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | PFIZER (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | PFIZER INC | 2005-09-22 | — | — | US | disclosed |
| WO-2005079807-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050171095-A1 | Combination of CRF antagonists and 5-HT1B receptor antagonists | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| WO-2005067973-A2 | COMBINATION OF CRF ANTAGONISTS AND 5-HT 1B RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-6900217-B2 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC (US) | 2005-05-31 | — | — | US | disclosed |
| US-20050009823-A1 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC | 2005-01-13 | — | — | US | disclosed |
| EP-1449532-A1 | Compound [2-(4-chloro-2,6-dimethyl-phenoxy)- 3,6-dimethyl-pyridin-4-yl]- (1-ethyl-propyl)- amine and use as CRF antagonist | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6777404-B2 | SUCH AS 3-((4-METHYL-BENZYL)-(3,6-DIMETHYL-1-(2,4,6-TRIMETHYLPHENYL)-1H-PYRAZOLO -(3,4-D)PYRIMIDIN-4-YL)-AMINO)PROP AN-1-OL FOR TREATING/PREVENTING SYNDROME X; KITS | PFIZER INC | 2004-08-17 | — | — | US | disclosed |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | PFIZER INC | 2004-04-29 | — | — | US | disclosed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | disclosed |
| US-6589947-B1 | Treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist. | PFIZER INC. | 2003-07-08 | — | — | US | disclosed |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | PFIZER INC. | 2002-10-24 | — | — | US | disclosed |
| US-20020151713-A1 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC. | 2002-10-17 | — | — | US | disclosed |
| US-6432989-B1 | TREATING SLEEP DISORDERS | PFIZER INC | 2002-08-13 | — | — | US | disclosed |
| US-20010041673-A1 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | PFIZER INC. | 2001-11-15 | — | — | US | disclosed |
| EP-1149583-A2 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | disclosed |
| US-20010007867-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | CHEN YUHPYNG L (US) | 2001-07-12 | — | — | US | disclosed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1082960-A2 | Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1082960-A2 | Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | CRH, MC2R, CRHR2 | NPY1R 54/4885CRHR1 5/4885TSHR 57/4885 |
| US-20050009823-A1 | Substituted 6,5-hetero-bicyclic derivatives | CYP2D6, CYP2B6, ABCG2 | NPY1R 1244/4885CRHR1 2433/4885TSHR 1133/4885 |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | NPY1R 82/4885CRHR1 2/4885TSHR 325/4885 |
| US-20010041673-A1 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | CRH, GHSR, GHRHR | NPY1R 35/4885CRHR1 4/4885TSHR 70/4885 |
| US-20020151713-A1 | Substituted 6,5-hetero-bicyclic derivatives | CYP2D6, CYP2B6, CYP3A5 | NPY1R 1588/4885CRHR1 2304/4885TSHR 2281/4885 |
| US-20050171095-A1 | Combination of CRF antagonists and 5-HT1B receptor antagonists | HTR2B, HTR1B, HTR3B | NPY1R 43/4885CRHR1 16/4885TSHR 176/4885 |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | CRH, CRHR1, CRHR2 | NPY1R 7/4885CRHR1 2/4885TSHR 122/4885 |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | NPY1R 82/4885CRHR1 2/4885TSHR 325/4885 |
| US-20010007867-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | CYP2D6, CYP2B6, CYP3A5 | NPY1R 1486/4885CRHR1 2026/4885TSHR 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.